Stock IRLAB A IRLAB THERAPEUTICS AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings IRLAB Therapeutics AB

Equities

IRLAB A

SE0012675361

Delayed Nasdaq Stockholm
Other stock markets
 07:05:09 2024-06-12 am EDT 		5-day change 1st Jan Change
13.65 SEK -1.44% Intraday chart for IRLAB Therapeutics AB -3.19% +82.00%
May. 27 Sweden’s IRLAB Therapeutics Names New CEO MT
May. 27 IRLAB Therapeutics AB Announces CEO Changes, Effective from August 1, 2024 CI

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the past twelve months, EPS forecast has been revised upwards.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • Based on current prices, the company has particularly high valuation levels.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
IRLAB THERAPEUTICS AB Stock IRLAB Therapeutics AB
+82.00% 68.32M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+48.53% 780B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+41.67% 627B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.37% 353B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.93% 334B
B-
ABBVIE INC. Stock AbbVie Inc.
+8.21% 296B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.89% 244B
B+
ROCHE HOLDING AG Stock Roche Holding AG
-0.98% 217B
A+
NOVARTIS AG Stock Novartis AG
+11.44% 214B
B-
AMGEN INC. Stock Amgen Inc.
+4.40% 161B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. IRLAB A Stock
  4. Ratings IRLAB Therapeutics AB